Breast Cancer: Characteristics, Diagnostic and Therapeutic Options and the Potential of Nanoparticle Applications
Source abstract
Abstract
Breast cancer is one of the most commonly diagnosed malignant tumors worldwide and represents a significant public health problem. This paper presents the characteristics of the disease, with particular emphasis on risk factors, mechanisms of development, and molecular classification. Current diagnostic methods and available therapeutic strategies, such as surgery, chemotherapy (CT), radiotherapy (RT), and targeted therapies, are discussed. Particular attention is given to nanotechnology as a promising direction for the development of modern medicine. The potential applications of nanoparticles (NPs) in the diagnosis and treatment of breast cancer are presented, taking into account their mechanisms of action, potential clinical benefits, and limitations related to safety and efficacy. NPs may contribute to increased diagnostic precision and therapeutic efficacy, indicating their significant potential in the future of oncology.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoparticles: synthesis and applications · Breast Cancer Treatment Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Health Sciences and Physical Culture, Casimir Pulaski Radom University, Street Chrobrego 27, 26-600 Radom, Poland
Department of Chemistry, Casimir Pulaski Radom University, Street Chrobrego 27, 26-600 Radom, Poland
Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland
References (100+)
Show source-provided references
1. Roheel, A., Khan, A., Anwar, F., Akbar, Z., Akhtar, M.F., Khan, M.I., Sohail, M.F., and Ahmad, R. (2023). Global Epidemiology of Breast Cancer Based on Risk Factors: A Systematic Review. Front. Oncol., 13.10.3389/fonc.2023.1240098 ↗
2. World Health Organization (2025). Breast Cancer 2025, WHO.
3. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
4. Breast Cancer: Presentation, Investigation and Management10.12968/hmed.2021.0459 ↗
5. Breast Cancer Statistics 2024
6. Breast Cancer: Biology, Biomarkers, and Treatments10.1016/j.intimp.2020.106535 ↗
7. Breast Cancer10.1016/S0140-6736(20)32381-3 ↗
8. Jian, S., Lin, W., Tang, Y., and Yao, G. (2025). Breast Cancer Burden (1990–2040) in Individuals Aged 55 and Above: A GBD 2021 Analysis of Global Trends, Sex-Specific Risk Factors, and Intervention Impact. Front. Public Health, 13.10.3389/fpubh.2025.1586497 ↗
9. Beňačka, R., Szabóová, D., Guľašová, Z., Hertelyová, Z., and Radoňák, J. (2022). Classic and New Markers in Diagnostics and Classification of Breast Cancer. Cancers, 14.10.3390/cancers14215444 ↗
10. Clinical Advances in PET–MRI for Breast Cancer10.1016/S1470-2045(21)00577-5 ↗
11. Recent Advances of Small Extracellular Vesicle Biomarkers in Breast Cancer Diagnosis and Prognosis10.1186/s12943-023-01741-x ↗
12. Review of Breast Cancer Pathologigcal Image Processing10.1155/2021/1994764 ↗
13. SEOM-GEICAM-SOLTI Clinical Guidelines for Early-Stage Breast Cancer (2022)10.1007/s12094-023-03215-4 ↗
14. Mundekkad, D., and Cho, W.C. (2022). Nanoparticles in Clinical Translation for Cancer Therapy. Int. J. Mol. Sci., 23.10.3390/ijms23031685 ↗
15. Awareness and Current Knowledge of Breast Cancer10.1186/s40659-017-0140-9 ↗
16. Modulation of the Tumor Microenvironment and Mechanism of Immunotherapy-Based Drug Resistance in Breast Cancer10.1186/s12943-024-01990-4 ↗
17. From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment10.2147/BCTT.S501448 ↗
18. Nanomedicine in Cancer Therapy10.1038/s41392-023-01536-y ↗
19. Subhan, M.A., Yalamarty, S.S.K., Filipczak, N., Parveen, F., and Torchilin, V.P. (2021). Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. J. Pers. Med., 11.10.3390/jpm11060571 ↗
20. Molecular Classification of Breast Cancer: A Retrospective Cohort Study10.1016/j.amsu.2019.11.021 ↗
21. Mayrovitz, H.N. (2022). Subtypes of Breast Cancer. Breast Cancer, Exon Publications.10.36255/exon-publications-breast-cancer ↗
22. Carvalho, E., Canberk, S., Schmitt, F., and Vale, N. (2025). Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies. Cancers, 17.10.3390/cancers17071102 ↗
23. Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., and Stanisławek, A. (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers, 13.10.3390/cancers13174287 ↗
24. Smolarz, B., Nowak, A.Z., and Romanowicz, H. (2022). Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers, 14.10.3390/cancers14102569 ↗
25. Histological and Molecular Classification of Breast Cancer: What Do We Know?10.29289/25945394202020200024 ↗
26. Pesapane, F., Sorce, A., Battaglia, O., Mallardi, C., Nicosia, L., Mariano, L., Rotili, A., Dominelli, V., Penco, S., and Priolo, F. (2025). Contrast Agents in Breast MRI: State of the Art and Future Perspectives. Biomedicines, 13.10.3390/biomedicines13040829 ↗
27. Li, H., Zhang, C., Shao, H., Pan, L., Li, Z., Wang, M., and Xu, S.-H. (2025). Prediction models of breast cancer molecular subtypes based on multimodal ultrasound and clinical features. BMC Cancer, 25.10.1186/s12885-025-14233-6 ↗
28. Molecular Subtypes and Imaging Phenotypes of Breast Cancer10.14366/usg.16030 ↗
29. Biological Subtype Predicts Locoregional Recurrence after Postmastectomy Radiotherapy in Chinese Breast Cancer Patients10.1002/cam4.2904 ↗
30. Molecular Subtypes of Breast Cancer Predicting Clinical Benefits of Radiotherapy after Breast-Conserving Surgery: A Propensity-Score-Matched Cohort Study10.1186/s13058-023-01747-9 ↗
31. Castro, M.M., Maretti, L., Esquível, C., Sousa, B., Jerónimo, C., Ewald, A.J., and Paredes, J. (2026). From luminal to triple negative: 3D spheroids reveal molecular and phenotypic differences across breast cancer subtypes. Preprints.10.20944/preprints202603.2418.v1 ↗
32. Mimicking 3D breast tumor-stromal interactions to screen novel cancer therapeutics10.1016/j.ejps.2023.106560 ↗
33. American College of Radiology (ACR) (2025). BI-RADS® V2025 Manual—What’s New?, American College of Radiology.
34. Magny, S.J., Shikhman, R., and Keppke, A.L. (2026). Breast Imaging Reporting and Data System. StatPearls, StatPearls Publishing.
35. Recent advances in breast imaging reporting: A review of the BI-RADS® sixth edition
36. Menon, G., Alkabban, F.M., and Ferguson, T. (2026). Breast Cancer. StatPearls, StatPearls Publishing.
37. Brierley, J.D., Giuliani, M., O’Sullivan, B., Rous, B., and Van Eycken, L. (2025). TNM Classification of Malignant Tumours, Wiley-Blackwell. [9th ed.].
38. The Impact of Dense Breasts on the Stage of Breast Cancer at Diagnosis: A Review and Options for Supplemental Screening10.3390/curroncol29050291 ↗
39. Nowoczesne Metody Obrazowania Zmian Rozrostowych Sutka—Nadzieje i Pułapki
40. Gadolinium Retention and Breast MRI Screening: More Harm Than Good?10.2214/AJR.19.21988 ↗
41. Iacobellis, F., Di Serafino, M., Russo, C., Ronza, R., Caruso, M., Dell’Aversano Orabona, G., Camillo, C., Sabatino, V., Grimaldi, D., and Rinaldo, C. (2024). Safe and Informed Use of Gadolinium-Based Contrast Agent in Body Magnetic Resonance Imaging: Where We Were and Where We Are. J. Clin. Med., 13.10.3390/jcm13082193 ↗
42. MRI Gadolinium-Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs
43. Gadolinium Contrast Agents—Challenges and Opportunities of a Multidisciplinary Approach: Literature Review10.1016/j.ejro.2023.100503 ↗
44. Unruh, C., Van Bavel, N., Anikovskiy, M., and Prenner, E.J. (2020). Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks. Molecules, 25.10.3390/molecules25235762 ↗
45. A Review of Gadolinium-Based Contrast Agents in the Setting of Repeated MRI for High Risk Breast Cancer Screening10.1016/j.clinimag.2025.110420 ↗
46. Breast cancer imaging without gadolinium-based contrast agent: A review of current applications and future trends10.1016/j.diii.2025.10.004 ↗
47. DWI in the assessment of breast lesions10.1097/RMR.0000000000000137 ↗
48. Update on DWI for breast cancer diagnosis and treatment monitoring
49. Wang, Z., Zhao, F., Zhu, L., Mao, N., Wang, W., Zhao, W., Yu, H., Li, Y., Li, C., and Yue, X. (2025). A multifunctional MRI model based on IVIM and DKI predicts HIF-1α, Ki-67, and VEGF status in breast carcinoma. Front. Oncol., 15.10.3389/fonc.2025.1652932 ↗
50. Synthetic MRI parameters and breast cancer heterogeneity: A quantitative study10.1016/j.acra.2025.11.001 ↗
51. Performance of dedicated breast PET in breast cancer screening: Comparison with digital mammography plus digital breast tomosynthesis and ultrasound10.1007/s12149-023-01846-9 ↗
52. Combined Use of Magnetic Seed and Tracer in Breast Conserving Surgery with Sentinel Lymph Node Biopsy for Non-Palpable Breast Lesions: A Pilot Study Describing Pitfalls and Solutions10.1016/j.suronc.2023.101905 ↗
53. Evaluation of Magseed Marker in Location of Non-Palpable Breast Lesions10.5604/01.3001.0016.0664 ↗
54. Safety and Efficacy of Magnetic Seed Localisation of Non-Palpable Breast Lesions: Pilot Study in a Chinese Population
55. Magnetic Seed (Magseed) Localisation in Breast Cancer Surgery: A Multicentre Clinical Trial10.1159/000510380 ↗
56. A Pilot Study Evaluating the Effects of Magtrace® for Sentinel Node Biopsy in Breast Cancer Patients Regarding Care Process Optimization, Reimbursement, Surgical Time, and Patient Comfort Compared With Standard Technetium9910.1245/s10434-020-09280-1 ↗
57. Use of Magtrace as an Alternative Approach in Staging the Axilla in Early-Stage Breast Cancer: A Single-Center Experience
58. Method for Grading Breast Cancer10.1136/jcp.46.2.189-b ↗
59. Systemic Therapy in Breast Cancer10.1200/EDBK_432442 ↗
60. Breast Cancer: Pathogenesis and Treatments10.1038/s41392-024-02108-4 ↗
61. Nanoparticle-Mediated Diagnosis, Treatment, and Prevention of Breast Cancer10.1039/D3NA00965C ↗
62. Aptamer Grafted Nanoparticle as Targeted Therapeutic Tool for the Treatment of Breast Cancer10.1016/j.biopha.2021.112530 ↗
63. Adjuvant and Neoadjuvant Breast Cancer Treatments: A Systematic Review of Their Effects on Mortality10.1016/j.ctrv.2022.102375 ↗
64. Novel Prevention Approaches of Breast Cancer Surgery Related Complications: Systematic Review and Network Meta-Analysis10.31557/APJCP.2024.25.1.9 ↗
65. Impact of Postmastectomy Radiotherapy on Locoregional Recurrence and Survival in Patients with ypN0 Breast Cancer after Neoadjuvant Chemotherapy: A Comprehensive Meta-Analysis and Systematic Review10.4103/jcrt.jcrt_1279_24 ↗
66. Overall Survival after Mastectomy versus Breast-Conserving Surgery with Adjuvant Radiotherapy for Early-Stage Breast Cancer: Meta-Analysis10.1093/bjsopen/zrae040 ↗
67. Impact of Neoadjuvant Chemotherapy on Surgical Complications in Breast Cancer: A Systematic Review and Meta-Analysis10.1016/j.ejso.2021.09.007 ↗
68. Advancements in Clinical Aspects of Targeted Therapy and Immunotherapy in Breast Cancer10.1186/s12943-023-01805-y ↗
69. A Review of Nanotechnology-Based Approaches for Breast Cancer and Triple-Negative Breast Cancer10.1016/j.jconrel.2020.07.003 ↗
70. Specific Targeting Cancer Cells with Nanoparticles and Drug Delivery in Cancer Therapy10.1016/j.semcancer.2019.11.002 ↗
71. Membrane-Wrapped Nanoparticles for Photothermal Cancer Therapy10.1186/s40580-022-00328-4 ↗
72. Herdiana, Y., Husni, P., Nurhasanah, S., Shamsuddin, S., and Wathoni, N. (2023). Chitosan-Based Nano Systems for Natural Antioxidants in Breast Cancer Therapy. Polymers, 15.10.3390/polym15132953 ↗
73. Biodegradable and Biocompatible Subcutaneous Implants Consisted of pH-Sensitive Mebendazole-Loaded/Folic Acid-Targeted Chitosan Nanoparticles for Murine Triple-Negative Breast Cancer Treatment10.1186/s12951-022-01380-2 ↗
74. Enhanced In Vivo Radiotherapy of Breast Cancer Using Gadolinium Oxide and Gold Hybrid Nanoparticles10.1021/acsabm.2c00965 ↗
75. Therapeutic Enhancement of Radiation and Immunomodulation by Gold Nanoparticles in Triple Negative Breast Cancer10.1080/15384047.2020.1861923 ↗
76. Penninckx, S., Heuskin, A.-C., Michiels, C., and Lucas, S. (2020). Gold Nanoparticles as a Potent Radiosensitizer: A Transdisciplinary Approach from Physics to Patient. Cancers, 12.10.3390/cancers12082021 ↗
77. Liang, P., Mao, L., Dong, Y., Zhao, Z., Sun, Q., Mazhar, M., Ma, Y., Yang, S., and Ren, W. (2021). Design and Application of Near-Infrared Nanomaterial-Liposome Hybrid Nanocarriers for Cancer Photothermal Therapy. Pharmaceutics, 13.10.3390/pharmaceutics13122070 ↗
78. Kim, D., and Kim, H. (2022). Optimization of Photothermal Therapy Treatment Effect under Various Laser Irradiation Conditions. Int. J. Mol. Sci., 23.10.3390/ijms23115928 ↗
79. Mechanisms of Immune Response to Inorganic Nanoparticles and Their Degradation Products10.1016/j.addr.2021.114022 ↗
80. Radiosensitization of Breast Cancer Cells Using AS1411 Aptamer-Conjugated Gold Nanoparticles10.1186/s13014-021-01751-3 ↗
81. Tuning Ultrasmall Theranostic Nanoparticles for MRI Contrast and Radiation Dose Amplification10.7150/thno.85663 ↗
82. Proof of Concept of the Radiosensitizing Effect of Gadolinium Oxide Nanoparticles in Cell Spheroids and a Tumor-Implanted Murine Model of Chondrosarcoma10.2147/IJN.S390056 ↗
83. Gadolinium Oxide Nanoparticles Reinforce the Fractionated Radiotherapy-Induced Immune Response in Tri-Negative Breast Cancer via cGAS-STING Pathway10.2147/IJN.S428044 ↗
84. Cancer-Targeted pro-Theranostic Bi-Metallic Organo-Coordination Nanoparticles10.7150/thno.99863 ↗
85. Sengupta, A., Azharuddin, M., Al-Otaibi, N., and Hinkula, J. (2022). Efficacy and Immune Response Elicited by Gold Nanoparticle-Based Nanovaccines against Infectious Diseases. Vaccines, 10.10.3390/vaccines10040505 ↗
86. Filipić, B., Pantelić, I., Nikolić, I., Majhen, D., Stojić-Vukanić, Z., Savić, S., and Krajišnik, D. (2023). Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines. Vaccines, 11.10.3390/vaccines11071172 ↗
87. Ninan, N., Goswami, N., and Vasilev, K. (2020). The Impact of Engineered Silver Nanomaterials on the Immune System. Nanomaterials, 10.10.3390/nano10050967 ↗
88. Smart Nanoparticles for Cancer Therapy10.1038/s41392-023-01642-x ↗
89. Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer10.2147/IJN.S388075 ↗
90. Trucillo, P., Campardelli, R., and Reverchon, E. (2020). Liposomes: From Bangham to Supercritical Fluids. Processes, 8.10.3390/pr8091022 ↗
91. Rani, R., Malik, P., Dhania, S., and Mukherjee, T.K. (2023). Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment. Pharmaceutics, 15.10.3390/pharmaceutics15010227 ↗
92. Aloss, K., and Hamar, P. (2023). Recent Preclinical and Clinical Progress in Liposomal Doxorubicin. Pharmaceutics, 15.10.3390/pharmaceutics15030893 ↗
93. Exosome-Sheathed Porous Silica Nanoparticle-Mediated Co-Delivery of 3,3′-Diindolylmethane and Doxorubicin Attenuates Cancer Stem Cell-Driven EMT in Triple Negative Breast Cancer10.1186/s12951-024-02518-0 ↗
94. Neoadjuvant Chemotherapy Using Nanoparticle Albumin-Bound Paclitaxel Plus Trastuzumab and Pertuzumab Followed by Epirubicin and Cyclophosphamide for Operable HER2-Positive Primary Breast Cancer: A Multicenter Phase II Clinical Trial (PerSeUS-BC04)10.1007/s12282-022-01425-2 ↗
95. Mesoporous Silica Nanoparticles Loaded with Resveratrol Are Used for Targeted Breast Cancer Therapy10.1155/2022/8471331 ↗
96. Mitochondria-Targeted Mesoporous Titanium Dioxide Nanoplatform for Synergistic Nitric Oxide Gas-Sonodynamic Therapy of Breast Cancer10.2147/IJN.S348618 ↗
97. Nanoparticles-Based Drug Delivery and Gene Therapy for Breast Cancer: Recent Advancements and Future Challenges10.1016/j.semcancer.2019.10.020 ↗
98. Nanotechnology for Breast Cancer Therapy10.1007/s10544-008-9209-0 ↗
99. Microneedles as Gateways: Smart Nanoparticle Delivery for Enhanced Breast Cancer Treatment10.1021/acsomega.5c04565 ↗
100. Artificial Intelligence-Assisted Design of Nanomedicines for Breast Cancer Diagnosis and Therapy: Advances, Challenges, and Future Directions10.1007/s12668-025-01980-w ↗